Payment overview · 2025
General Payments
$149.65
3 reported records · 3 companies
Healthcare provider profile · identity verified
Michael I Anstead, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, KY · NPI 1245259035
Verified facts
What the public records show
CMS Open Payments records show Michael I Anstead, MD received $149.65 in general payments during 2025 across 3 reported records.
Digestive Care, Inc. accounted for 46.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nucala, Pertzye.
Digestive Care, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Pertzye as an associated drug or biological on 417 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Pertzye by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
VERTEX PHARMACEUTICALS INCORPORATED reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRIKAFTA as an associated drug or biological on 29 records involving 20 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Trikafta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Digestive Care, Inc. | Unresolved — no canonical attribution shown | $69.30 | 46.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $66.05 | 44.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.30 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $149.65 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Pertzye Normalized: pertzye |
Drug | Digestive Care, Inc. | $69.30 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUCALA nucala |
2025 | Nucala | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Pertzye pertzye |
2025 | Pertzye | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Digestive Care, Inc. Exact reporting entity; no affiliate inference |
2025 | Pertzye open payments reported associated product |
CMS Open Payments — General Payments 417 supporting records · 327 recipient NPIs · example record 1173586522 |
Pertzye · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| VERTEX PHARMACEUTICALS INCORPORATED Exact reporting entity; no affiliate inference |
2025 | TRIKAFTA open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 20 recipient NPIs · example record 1213788219 |
Trikafta · 2024 Exact normalized brand match · 1 Part D row |
179 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trikafta | Elexacaftor/Tezacaftor/Ivacaft | 179 | 28 |
| Azithromycin | Azithromycin | 177 | 41 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 126 | 31 |
| Prednisone | Prednisone | 84 | 30 |
| Montelukast Sodium | Montelukast Sodium | 80 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 17 |
| Gabapentin | Gabapentin | 65 | 22 |
| Valganciclovir Hcl | Valganciclovir Hcl | 61 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 11 |
| Creon | Lipase/Protease/Amylase | 53 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 20 |
| Famotidine | Famotidine | 41 | 14 |
| Colistimethate | Colistin (Colistimethate Na) | 40 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 33 | 12 |
| Zenpep | Lipase/Protease/Amylase | 33 | suppressed |
| Tacrolimus | Tacrolimus | 32 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 29 | suppressed |
| Furosemide | Furosemide | 27 | 13 |
| Omeprazole | Omeprazole | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | 14 |
| Nucala | Mepolizumab | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Cayston | Aztreonam Lysine | 20 | suppressed |
| Posaconazole | Posaconazole | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Rifabutin | Rifabutin | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Fluconazole | Fluconazole | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Prevymis | Letermovir | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Pertzye | Lipase/Protease/Amylase | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Xolair | Omalizumab | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $149.65 · 3 records | Digestive Care, Inc. | NUCALA, Pertzye | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nucala play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Digestive Care, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error